Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Arnhem – page 57

787 clinical trials in Arnhem, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Arnhem at a glance
787
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

787 trials in Arnhem

Open in trial search

Fungal infection

Not recruiting

Study on the Effectiveness and Safety of Olorofim vs. Liposomal Amphotericin B for Patients with Invasive Aspergillosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Olorofim
  • Sponsor:F2G Limited

Cardiac failure chronic

Not recruiting

Study on the Effects of AZD5462 for Patients with Stable Chronic Heart Failure

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:AZD5462
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

C3 glomerulopathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Complement 3 Glomerulopathy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Chronic myeloid leukaemia

Not recruiting

Comparison of nilotinib versus imatinib treatment in newly diagnosed chronic myeloid leukemia patients to achieve treatment-free remission

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Malignant melanoma stage III

Not recruiting

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Gouty arthritis+1

Not recruiting

Study on Gout Treatment: Comparing Allopurinol, Benzbromarone, and Febuxostat in Patients with Gout in Remission

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Allopurinol
  • Sponsor:Sint Maartenskliniek

Non-small cell lung cancer stage III

Not recruiting

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Deafness neurosensory

Not recruiting

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:AudioCure Pharma GmbH

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Arnhem

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on advanced gastric cancer, bladder cancer, and various forms of leukemia. Studies include evaluation of novel imaging techniques and combination therapies for better treatment outcomes.

  • Gastric Cancer Staging
  • Bladder Cancer Therapeutics
  • Acute Myeloid Leukemia Treatment

Multiple trials exploring targeted therapies and innovative diagnostic approaches for various cancer types.

02 Cardiovascular Research

Comprehensive studies addressing cardiovascular disease management and prevention, including research on post-stroke care and cardiac arrest treatments.

  • Stroke Treatment Protocols
  • Cardiac Arrest Management
  • Cardiovascular Risk Reduction

Focus on improving patient outcomes through innovative therapeutic approaches and prevention strategies.

03 Metabolic Disorders

Clinical investigations targeting obesity and weight management, with emphasis on new therapeutic agents and their cardiovascular safety profiles.

  • Weight Management Therapies
  • Metabolic Disease Treatment
  • Safety Assessments

Evaluating novel approaches to treating metabolic disorders and their associated complications.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.